ITC to investigate Alvotech’s Humira biosimilar

The US International Trade Commission (ITC) will investigate whether drug manufacturers used trade secrets to develop a biosimilar of AbbVie’s Humira (adalimumab).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

AbbVie wants USITC to investigate Alvotech over Humira ‘theft’

21 December 2021 AbbVie seeks to block imports of Alvotech’s biosimilar Humira into the US, claiming that the Icelandic company plundered former employees and used its trade secrets to develop the drug.

Americas

Humira buyers appeal AbbVie ruling to Seventh Circuit

31 July 2020 Buyers of AbbVie’s arthritis treatment Humira have appealed against an Illinois judge’s decision to dismiss their class action antitrust suit to the US Court of Appeals for the Seventh Circuit.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

ITC to investigate Alvotech’s Humira biosimilar

More on this story

Editor's picks

Editor's picks

More features